


Horizon Europe

Framework programme for research and innovation 2021–2027

Meeting etiquette

- Digital meeting, please keep your mic on mute!
- Please hold on to your questions until the discussion part in the end of the session.
- Please raise your hand when you would like to ask a question during the Q&A or place your question in the chat.
- The presentation will be available to download after the meeting on the same page where you registered.



Agenda

- Horizon Europe – the last big round of funding!
- Cluster 1, health – upcoming opportunities and novelties

Break

- Mission Cancer – upcoming opportunities and novelties
- Support



The Horizon framework
programme is a
POLITICAL INSTRUMENT
where research and
innovation are needed to
achieve political priorities



2026-27: The last big round of funding

Drafts! Changes can be made until publication.

Ca. 25 BEUR in total (12,9 BEUR 2026, 12 BEUR 2027)

1 446 MEUR for CL1 (665 MEUR 2026, 781 MEUR 2027)

Publication: ± December 2025

Opening: Feb 2026, Feb 2027

Deadlines: April 2026, April 2027 (2nd stage Sept 2027)

243 MEUR for Mission Cancer (126 MEUR 2026, 117 MEUR 2027)


Publication: ± December 2025

Opening: Feb 2026, Feb 2027

Deadline: September 2026, September 2027



Horisont Europa



An eligible and competitive proposal

Fulfilling the eligibility rules:

- Min. 3 independant entities from 3 different memberstates or associated countries, of which at least one from a memberstate
- Fullfilling additional rules and prerequisites stipulated in the call text and topic text

EC "Best value for money":

- Multi-disciplinary consortium composed of the most suitable organisations to tackle the challenge outlined in the topic – no more and no less!
- Documentet excellence and adequate resources, as well as a concrete, detailed plan

Participation of non-EU-countries

- **Associated countries**

Participate under equivalent conditions as legal entities from the EU Member States, unless otherwise specified.

- **Third countries automatically eligible for funding** (if not subjected to EU restrictive measures)
Include many low- and middle-income countries

A full list of associated countries and third countries eligible for funding is found [here](#)

- **Other third countries**

Can usually participate in projects ***at their own cost*** (unless otherwise specified)
In exceptional cases they can be eligible for funding

- **Mind the additional rules and prerequisites** stipulated in each individual call text!

Some overarching issues

- Any legal entity established in the **United States of America is eligible to receive Union funding**. (CL 1 only, *not* Mission Cancer!)
- **Lump sum**: a different type of budget, no reporting of actual costs
- **Blind evaluation**: organisations not to be disclosed in 1st stage (short) proposal
- The active involvement of **relevant stakeholders** (e.g. patients, civil society, clinicians, regulators) is strongly encouraged (most topics)
- Contribution of social sciences and humanities (**SSH**) disciplines (most topics)
- The participation of start-ups, micro, small and medium-sized enterprises (**SMEs**) is encouraged (many topics)
- For **clinical studies** a specific **template** should be used (whenever a clinical study is proposed)
- Subject to restrictions for the protection of European communication networks (some topics)
Entities that are assessed as **high-risk suppliers** of mobile network communication equipment (and any entities they own or control) are not eligible to participate. More info in [Annex B](#)

CL1 - Health

Aims

- to better understand and manage health and diseases
- sustainable digital transformation
- delivery of integrated, person-centred and equitable health and care
- reliable supply chains



Overview

- Staying healthy in a rapidly changing society (STAYHLTH)
- Living and working in a health-promoting environment (ENVHLTH)
- Tackling diseases and reducing disease burden (DISEASE)
- Ensuring equal access to innovative, sustainable, and high-quality healthcare (CARE)
- Developing and using new tools, technologies and digital solutions for a healthy society (TOOL)
- Maintaining an innovative, sustainable, and competitive EU health industry (IND)



Deadlines and conditions per call

Overview of this call ³²				
Proposals are invited against the following Destinations and topic(s):				
Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million) ³³	Indicative number of projects expected to be funded
Opening: 10 Feb 2026 Deadline(s): 16 Apr 2026				
Destination - Staying healthy in a rapidly changing society				
HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people	RIA	21.00	9.00 to 10.00	2
Destination - Living and working in a health-promoting environment				
HORIZON-HLTH-2026-01-ENVHLTH-01:	RIA	55.00	7.00 to 8.00	7
Opening: 10 Feb 2027 Deadline(s): 13 Apr 2027 (First Stage), 22 Sep 2027 (Second Stage)				

Destination

Policy context, expected impact

Individual topic identifier

Title, text (scope, expected outcomes, additional rules)

Table of contents

Introduction 6

Calls 13

Call - Cluster 1 - Health (Single stage - 2026)..... 13

Overview of this call 13

Call - Partnerships in Health (2026/1)..... 16

Overview of this call 16

Call - Partnerships in Health (2026/2)..... 17

Overview of this call 17

Call - Partnerships in Health (2026/3)..... 18

Overview of this call 18

Call - Cluster 1 - Health (Single stage - 2027/1)..... 19

Overview of this call 19

Call - Cluster 1 - Health (Two stage - 2027)..... 22

Overview of this call 22

Call - Cluster 1 - Health (Single stage - 2027/2)..... 23

Overview of this call 24

Destinations 26

Destination - Staying healthy in a rapidly changing society..... 26

HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion 28

HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people 32

Destination - Living and working in a health-promoting environment 35

HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health 36

HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change 41

Staying healthy in a rapidly changing society

STAYHLTH

1 topic 2026, 1 topic 2027

Impacts:

- develop healthier lifestyles, behaviors and choices and maintain a longer, independent and active life
- empowered to effectively manage their physical and mental health and wellbeing
- Society benefits from reduced economic and health burdens

Staying healthy in a rapidly changing society

- i) addressing disabilities through the life course to support independent living and inclusion, with an emphasis on empowering persons with disabilities and their families. [...]

HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion

- ii) developing behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs), with an emphasis on promoting healthy habits and sustained behavioural change among youth. [...]

HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people

Living and working in a health-promoting environment

ENVHLTH

- 3 topics 2026, 2 topics 2027

Impacts:

- Sustainable and science-based policy
- Health threats from hazardous chemicals and pollution are lessened
- Living and working environments are healthier, more inclusive, safer, resilient and sustainable
- Climate adaptation for health
- Citizens' health and health literacy promoted, inequalities are reduced

Living and working in a health-promoting environment

2026:

- impact of climate change on health
- climate resilient, prepared and carbon neutral populations and healthcare systems
- Support for a multilateral initiative on climate change and health research (CSA for building a platform!)

2027:

- Integration of climate-related exposures into the human exposome

New: a joint topic between CL1 and Mission Climate Adaptation in 2027:

HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change (a PCP!)

Living and working in a health-promoting environment

All proposals involving the development, use and/or deployment of AI based system/technique should ensure that the proposed AI system/technique is technical robust, safe and must describe how they will uphold the principles of human agency and oversight, fairness, diversity, non-discrimination, societal and environmental well-being, transparency and accountability.

[Ethics Guidelines for Trustworthy AI](#)

[Ethics by Design and Ethics of Use Approaches for Artificial Intelligence](#)

Tackling diseases and reducing disease burden

DISEASE

- 6 topics 2026 (2 European partnerships), 7 topics 2027

Impacts:

- Disease burden, premature mortality from NCDs and threat from cross-border health risks and AMR are reduced in the EU and world-wide
- Increased health literacy

Tackling diseases and reducing disease burden

- i) new treatment and disease management options to reduce burden on non-communicable diseases and long-term conditions after post-bacterial and post-viral infections
- ii) improve and protect mental health of children and young adults
- iii) new prevention and treatment options for infectious diseases with epidemic potential
- iv) innovative therapies for AMR critical pathogens

Tackling diseases and reducing disease burden

2026:

- Effects of digital technologies on mental health (children, youth)
- Post-infection long-term conditions
- Vaccin development
- Implementation research on NCDs
- Sex/gender-specific mechanisms in CVD
- Scaling up innovation in cardio-vascular health

2027:

- NCDs healthcare and prevention in children and young people (2 topics)
- Broad-spectrum small molecular antivirals
- mABs for prevention and treatment of infections with Flaviviridae, and with Filo-, Nairo-, Phenui-, Picorna- and Toga Viridae (2 topics)
- Antimicrobials against critical pathogens resistant to current antimicrobials
- Clinical trials for interventions for neurodegenerative diseases

Ensuring equal access to innovative, sustainable, and high-quality healthcare

CARE

- 2 topics 2026 (1 European partnership), 1 topic 2027

Impacts:

- more effective, efficient, accessible, resilient, trusted and sustainable health care and social care
- people-centred healthcare structures, prioritising health promotion and disease prevention
- competence and skills
- access to high quality healthcare services
- inclusion

Ensuring equal access to innovative, sustainable, and high-quality healthcare

- HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated and personalised approaches (PPI!)
- HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
- HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Developing and using new tools, technologies and digital solutions for a healthy society

TOOL

- 1 topic 2026 (1 ERA Action), 5 topics 2027

Impacts:

- EU's visibility and leadership
- Safer, more sustainable, efficient, cost-effective and affordable tools, technologies and digital solutions
- Improved, secure and ethical use of health data and innovative analytical tools
- Public trust

Developing and using new tools, technologies and digital solutions for a healthy society

2026:

- New Approach Methodologies (NAMs)

2027:

- predictive biomarkers of disease progression and treatment response (chronic NCDs)
- bio-printing of living cells for regenerative medicine
- Virtual Human Twins for clinical decision making
- Artificial general intelligence (AGI) for healthcare (CSA)

New: a topic for follow-up funding in 2027:

HORIZON-HLTH-2027-01-TOOL-05: Pilot Actions for Follow-on Funding: Leveraging EU-funded Collaborative Research in Regenerative Medicine

- ✓ Projects funded under HE or H2020 (excl. MSCA)
- ✓ Projects completed max 3 years prior to submission

Maintaining an innovative, sustainable, and competitive EU health industry

IND

- 1 topic 2026, 2 topics 2027

Impacts:

- more competitive and sustainable health industry, creating jobs and economic growth
- value chain from the identification of needs to the scale-up and take-up of solutions
- swift uptake of innovative health technologies and services
- reliable access to key manufacturing capacity, critical supply and distribution chains

Maintaining an innovative, sustainable, and competitive EU health industry

“focuses on collaborative efforts to advance cell-free protein synthesis platforms, ready-to-use point-of-care diagnostics, and regulatory science to support translational development of patient-centered health technologies.”

- HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics

4 two-stage topics planned

- HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases
- HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics



Support

European Commission

[Pre-published draft CL 1](#)

[EU Funding & Tenders Portal](#)
(information and application)

[Research Enquiry Services](#)
(answers and support)

[NCP search engine](#)
(contacts to NCPs in other countries)

Sweden

[National Contact Points:](#)

Nadine Schweizer: nadine.schweizer@vinnova.se

Susanne Frykman: susanne.frykman@vr.se

Aiga Giangiacomo: aiga.giangiacomo@forte.se

[EU SME support](#)

[Vinnova's Planning grant for international proposals](#)

Closing date: 12 Nov 2025



**BREAK
TIME!!!**

Mission Cancer

Mission areas

Missions are not only about R&I – focused on delivering a public good.

They are used to agree on a European level what we want to change and deliver it in society.

1



**Adaptation to
Climate Change**

2



Cancer

3



**Restore our Oceans
and Waters**

4



**Climate-Neutral and
Smart Cities**

5



**A Soil Deal for
Europe**

A mission-driven approach

- Seeing cancer as a societal challenge
- Cross sectorial and multidisciplinary, even at governance level
- Focus on synergies and some strategic actions aiming at coordinating the cancer innovation system at EU and national levels.
- New calls build on previous and ongoing initiatives ([Implementation Plan](#))



Implementation of Mission Cancer

Two "intertwined" EU initiatives



Mission Cancer

improving the lives of more than 3 million people by 2030 through prevention, cure and for those affected by cancer including their families, to live longer and better



4 objectives:

1. Understand Cancer
2. Prevention and early detection
3. Diagnosis and treatment
4. Quality of life for patients and survivors

5 transversal priorities:

1. Equitable access
2. Childhood cancer
3. Innovation
4. Personalised medicine
5. Citizen engagement



Cancer Mission: flagship initiatives



Understand

ACCESS

Uncan.eu: aiming at improving understanding of cancer mechanisms



Prevention

EQUIT
ABLE

European Cancer Prevention Centre: aiming at providing evidence on cancer prevention



Diagnostic
& treatment


ENSURE

Network of Comprehensive Cancer Infrastructures: aiming at strengthening research capacities of CCIs



Support QoL

European Cancer Patient Digital Centre: aiming at supporting QoL of patients



Understand

- **HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research**

Understand

- **HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research**
- **HORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to reveal novel targets for cancer treatment**

Understand

- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
- HORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to reveal novel targets for cancer treatment
- **HORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research**

Prevention

- **HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before onset of disease**

Diagnosics & Treatment

- HORIZON-MISS-2027-02-CANCER-02: Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers across Europe

Diagnosics & Treatment

- **HORIZON-MISS-2027-02-CANCER-02:** Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
- **HORIZON-MISS-2027-02-CANCER-03:** Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Diagnosics & Treatment

- **HORIZON-MISS-2027-02-CANCER-02: Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers**
- **HORIZON-MISS-2027-02-CANCER-03: Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes**
- **HORIZON-MISS-2027-02-CANCER-05: Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines**

Diagnostics & Treatment / Ensure equitable access

- **HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancer**

Support Quality of Life

- **HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care**

Support Quality of Life

- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2027-02-CANCER-06: Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies

Support Quality of Life

- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2027-02-CANCER-06: Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)

Support Quality of Life

- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2027-02-CANCER-06: Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
- HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of elderly cancer patients

Other calls

- **HORIZON-MISS-2026-02-CANCER-06: Development of a capacity building programme on cancer research with and for Ukraine**

National Cancer Mission Hub

The Coordination Support Action ECHoS is developing methods and guidelines for National Cancer Mission Hubs to coordinate relevant stakeholders in cancer-related policy dialogues.

National Cancer Mission Hubs are being established in Member States, and SoS is planning for a national version adapted to the Swedish context.

Contact: cancer@socialstyrelsen.se



Support on EU level

- Learn more about the [Project Clusters](#)
 - [Upcoming webinar](#) with Diagnostics and Treatment Cluster – 3 november 2025
- Explore the [Cancer Mission Implementation Platform](#) and their [newsletter](#) for the latest updates
- Explore [Cancer project dashboard](#) of EU Knowledge Centre on Cancer
- Become an [EU Cancer Mission Ambassador](#)

Cancer Group	
Blood cancers	Gastrointestinal cancers
Genital System, Female	Genital System, Male
Head and Neck Cancer	Nervous System
Other cancers	Respiratory System
Sarcoma	Urinary System
(tom)	

Cancer Site (CSO)	
Anal Cancer	Bladder Cancer
Blood Cancer	Bone Cancer, Osteos...
Bone Marrow Transpl...	Brain Tumor
Breast Cancer	Cervical Cancer
Colon and Rectal Ca...	Ear Cancer
Endometrial Cancer	Esophageal / Oesoph...
Eye Cancer	Gallbladder Cancer
Hodgkins Disease	Kaposi's Sarcoma
Kidney Cancer	Leukemia / Leukaemia
Liver Cancer	Lung Cancer
Melanoma	Myeloma
Nasal Cavity and Par...	Neuroblastoma
Non-Hodgkins Lymph...	Oral Cavity and Lip C...
Ovarian Cancer	Pancreatic Cancer
Pituitary Tumor	Primary CNS Lympho...
Prostate Cancer	Retinoblastoma
Salivary Gland Cancer	Sarcoma
Sarcoma, Rhabdomy...	Sarcoma, Soft Tissue
Skin Cancer	Small intestine cancer

Funding Programme			
3rd Health Programme	Connecting Europe Facility	Connecting Europe Facility (CEF)	Creative Europe Prog
Erasmus+ (ERASMUS+)	EU4Health Programme (EU4H)	European Maritime and Fisheries Fund	European Social Fun
HORIZON 2020	HORIZON EUROPE	Internal Security Fund Police	Interregional Innovat
Promotion of Agricultural Products (AGRIP)	Technical Support Instrument (TSI)	The European Union programme for educ...	

4 106									
Relevance	projectid	acronym	title	objective	euroSciVoc	freeKeywords	stat		
3	101154177	MarrowMimi	A bone marrow mimicry	Hematopoietic	bioreactors; leukemia	tissue engineering,	SIGN		
3	101147615	NanoCHROMS	Nanoscale Chromatin	Cells respond to	DNA; cell biology;	Chromatin structure,	SIGN		
18	101152312	UBImmune	Identification of novel	Immunotherapies have	lung cancer; proteins;	Cancer immunology,	SIGN		
20	101155175	HIFCAT	HIF-1α in	Colorectal cancer	mortality; immunology;	Colorectal cancer,	SIGN		
2	101152617	EARLINESS	Early and sensitive	Systemic lupus	mortality;	Non-invasive	SIGN		
15	101152137	RETRO	Relapse in T-ALL:	T cell acute	mutation;	Cancer relapse, T cell	SIGN		
1	101153580	NanoACATre	Rational Design of ACAT	Hepatic fibrosis is a	synthetic biology;	Bottom-up Synthetic	SIGN		
20	101146541	SMART-NHL	Studying the	The tumor	oncology; pathology;	Precinical medicine,	SIGN		
12	101163784	ADRIIP	Unraveling mechanisms	Pancreatic cancer is	prostate cancer;	Kras Inhibitor Drug	SIGN		
1	101152302	SPADYN-SM	Spatiotemporal	Microbial secondary	proteins; mutation;	marine microbiology,	SIGN		
8	101150601	DEXTER	Development of	In spite of a growing	cell biology;	Extracellular vesicles,	SIGN		
3	101149037	Waste2Drug	Valorisation of	Sustainability is a major	medicinal chemistry;	target identification,	SIGN		
2	101146540	Stem2MorphoMap	Deciphering the	Tissue development	genetic engineering;	Branching	SIGN		
2	101147418	TE-Time	Dissecting	Mammalian genomes	DNA; oncology;	Transposable elements	SIGN		
2	101151489	GLUCHIRAL	Molecular chirality tools	Celiac disease (CD) is a	immunology; nutrition;	Celiac disease, gluten	SIGN		
2	101179234	INTERACT	Interdisciplinary Marie	The last decades are		interdisciplinary STEM	SIGN		
1	101153920	BIOinFILM	Shedding light on the	Bacterial biofilms are	biomolecules;	Bacterial biofilms,	SIGN		
9	101153103	Rewiring PRC2	Rewiring transcriptional	Polycomb repressive	proteins; oncology;	Polycomb repressive	SIGN		
2	101153296	LIMITS	Lipid Inclusions	Each year, 1.1 million	lipids; oncology; stroke;	Lipid droplets, PLIN2,	SIGN		
15	101164555	TOCCATA	Total Optical	Drug resistance,	oncology	optical properties,	SIGN		
8	101154630	EpiMetaPDO	Dissecting mechanisms	Cancer development is	colorectal cancer;	Metastasis,	SIGN		
10	101154299	IN-FACT	Initiation Factor 3 as	Eukaryotic translation	proteins; oncology	eIF3, Cancer, Drug	SIGN		
5	101163850	TrapKill	Trapping and Killing	Glioblastoma	DNA; oncology;	Biomaterials,	SIGN		
19	101141357	MechanoResistance	Overcoming	Cancer progression is	immunotherapy;	Bioengineering,	SIGN		
6	101168810	T-RAFIC	Training network for	Cancer	oncology;	T-RAFIC	SIGN		
4	101165259	Tightly Controlled	Tight junctions and	One of the most	gene therapy; proteins;	Salamander, Heart	SIGN		
3	101151748	LYMON	Laser-assisted	Catalysis holds	drug discovery;	laser-synthesis,	SIGN		
2	101179116	MAP-ID	Multilevel approaches	The MAP-ID project	biochemistry;	chronic inflammatory	SIGN		
8	101180630	TissueEng	3D bioprinting	Bone tissue engineering	biochemistry; cell	Injectable hydrogel,	SIGN		
10	101165045	LIFETIME	Lifetime Metabolomics	"Understanding cancer	liver cancer; organ on a	hyperpolarization, MRI,	SIGN		
16	101164852	eMOCA	Early Multi-Omic	Lung cancer is a leading	prostate cancer;	Metagenomics,	SIGN		

Support from Vinnova

- Contact your NCP
 - Jonathan Nylander, NCP EU Missions
jonathan.nylander@vinnova.se
- Get e-mail updates regarding the EU Missions
- Latest public draft of EU Missions work programme 2026-2027



